Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to five newly hired employees on February 27, 2026, totaling 46,200 shares.
The options carry an exercise price of $1.31 (equal to closing price on the grant date), vest over four years (25% after one year, then quarterly), and have a 10-year term under Akebia's inducement award program.
Akebia Therapeutics (Nasdaq: AKBA) reported Q4 2025 net product revenues of $54.3M and full‑year 2025 net product revenues of $227.3M, a 49% increase versus 2024. Vafseo patient access reached 290,000; company expects significant 2026 Vafseo revenue growth. Cash totaled $184.8M, sufficient to fund operations for at least two years. Pipeline progress includes a Phase 2 praliciguat FSGS trial enrolling and a planned 2H 2026 AKB-097 Phase 2 rare kidney disease basket study.
Akebia Therapeutics (Nasdaq: AKBA) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before market open. A conference call to discuss results and recent business highlights will be held on Thursday, February 26, 2026 at 8:00 a.m. EST.
Investors must register to receive dial‑in details; a live webcast and an online archive will be available via the Investors section of Akebia's website.
Akebia Therapeutics (Nasdaq: AKBA) said its executive team will take part in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 AM EST.
A webcast will be available via the company’s Investors site after the conference. The summit runs February 11-12, 2026 in New York City.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to two newly hired employees on January 30, 2026, covering an aggregate of 132,675 shares. The options carry a $1.41 exercise price (equal to the closing price on the grant date), vest over four years and have a 10-year term.
The awards were made under Akebia’s inducement award program in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms of the stock option agreements and continued service.
Akebia Therapeutics (Nasdaq: AKBA) provided 2026 corporate updates focused on Vafseo commercial progress and its mid‑stage rare kidney disease pipeline. The company said it has prescribing access covering ~275,000 dialysis patients, completed enrollment in the Phase IV VOICE trial (>2,100 patients) with topline results expected in early 2027, and enrolled ~350 patients in VOCAL with data expected in Q4 2026. Akebia reported Q4 2025 Vafseo net product revenue expectation of $5–$6 million (impacted by a $4.5–$5 million channel inventory reduction) and said revenue growth is expected to resume in Q1 2026. Pipeline updates include first patient dosed in praliciguat Phase 2 for FSGS (Dec 2025) and a planned AKB-097 Phase 2 basket trial starting 2H 2026 with initial data expected in 2027.
Akebia Therapeutics (Nasdaq: AKBA) announced that the first patient has been dosed in a Phase 2 randomized, double-blind, placebo-controlled study of oral once-daily praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS).
The study will randomize ~60 adults on maximally tolerated ACEi/ARB therapy 1:1 to praliciguat or placebo for a 24-week double-blind period followed by a 24-week open-label extension. The primary endpoint is change in urine protein-to-creatinine ratio (UPCR) at Week 24; a key secondary endpoint is partial remission defined as 40% UPCR reduction and UPCR <1.5 g/g.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to a newly hired employee on December 31, 2025 under Nasdaq Listing Rule 5635(c)(4).
The grant covers 197,900 options with an exercise price of $1.61 per share (equal to the closing price on the grant date). Options vest over four years (25% on the first anniversary, then quarterly thereafter), each option has a 10-year term, and awards are subject to Akebia’s inducement award program and a stock option agreement.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to two newly hired employees on November 28, 2025 under Nasdaq Listing Rule 5635(c)(4).
The awards total 22,576 options with an exercise price of $1.58 per share (equal to the closing price on the grant date). Options vest over four years (25% at the first anniversary, then quarterly vesting for the remaining 75%), have a 10-year term, and are governed by Akebia’s inducement award program and stock option agreement.
Akebia (Nasdaq: AKBA) announced the establishment of a rare kidney disease pipeline on Dec 1, 2025, centered on two candidates: AKB-097 (a tissue-targeted C3d‑Factor H fusion protein complement inhibitor acquired from Q32 Bio) and praliciguat (an sGC stimulator).
Akebia acquired all rights to AKB-097 and says it targets complement activation sites without expected systemic complement inhibition. A Phase 2 trial of praliciguat in FSGS has been initiated, and both Phase 2 programs are planned to begin treating subjects in 2026. Akebia expects AKB-097 Phase 2 basket trial data beginning in 2027.